Apr 29, 2024 · The risk of clozapine-induced agranulocytosis decreases steeply over time but might be persistently greater than that of non-clozapine antipsychotics. This long-term risk …

Clozapine exhibits significant therapeutic efficacy in schizophrenia, especially treatment‐resistant schizophrenia. However, clozapine can cause agranulocytosis, a fatal adverse effect, and the …

Jun 11, 2024 · The risk of agranulocytosis is slightly elevated in females [10], while individuals of Asian descent display a 2.4-fold higher risk compared to those of Caucasian descent [11]. In …

Clozapine is the only evidence-based intervention for treatment-resistant schizophrenia. One of the drug's most well-known and potentially fatal adverse effects is agranulocytosis (severe …

Jul 15, 1993 · The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count. The increasing …

Jul 10, 2025 · Learn about the link between clozapine and agranulocytosis, and the essential safety monitoring framework that allows for its effective clinical application.

Agranulocytosis, a well-known risk associated with the use of clozapine, is minimised through routine haematological monitoring, as outlined in the summary of product characteristics (SmPC).

Jul 7, 2010 · The risk of agranulocytosis—a severe loss of white blood cells—among people taking clozapine is minimal and drops steeply after the first year of use, according to a recent …

Agranulocytosis occurs in up to 0.8% of patients and presents a significant medical challenge, despite decreasing mortality rates. In this paper, we review the epidemiology of clozapine …

May 28, 2024 · Agranulocytosis risk associated with clozapine treatment decreased over time, but remained greater than non-clozapine antipsychotics.